Journal of Developmental Medicine(Electronic Version)  2020, Vol. 8 Issue (2): 163-167 DOI: 10.3969/j.issn.2095-5340.2020.02.013 |
|
|
|
|
|
|
| Efficacy and mechanism of gestrinone combined with ethinyl estradiol progesterone in the treatment of endometriosis |
| Li Yunli, Zhang Qin, Yang Zhengqin，et al
|
| (1. Department of Obstetrics and Gynecology,Lu'an People's Hospital, Anhui, Lu'an 237005, China; 2. Department of Gynaecology, Jiangsu ProvincialHospital of Chinese Medicine, Jiangsu, Nanjing 210029, China) |
|
|
|
Abstract 【Abstract】 Objective To compare the difference in efficacy between ethynylestradiol cyproterone(ETCY) and ETCY combined with gestrinone (GES) in the treatment of endometriosis, and to investigate effects of two therapies on serum and peritoneal fluid activated regulator of T lymphocyte secretion(RANTES) and the levels of T cell subpopulations in peripheral blood. Methods From May 2015 toMay 2018, 131 patients with endometriosis were enrolled in the Lu'an People's Hospital. The 131 caseswere randomly divided into control group (66 cases) and study group (65 cases) by random number tablemethod. The control group was treated with ETCY for 6 months and meanwhile conventional oral liverprotection drugs were used. The study group added GES treatment based on the treatment of control group.RANTES levels were detected by enzyme-linked immunosorbent assay (ELISA) in preoperative serum,intraoperative peritoneal fluid, and serum after 6 months since surgery. Flow cytometry was used to detectthe level of T cell subsets after 6 months since surgery. The efficacy and adverse reaction indicators weresummarized. Statistical analysis was performed by independent sample t-test and χ2 test. Results There
was no statistical significance in age and duration of disease between the two groups (P>0.05). At 6 monthsafter surgery, the total effective rate in the study group was higher than that in the control group [96.9% (63/65)vs 84.8% (56/66), χ2=5.738, P=0.017]. There was no statistical significance in the incidence of adversereactions (hepatic function injury, irregular vaginal bleeding, rash and stomach upset) between the two groups(all P>0.05). There were no statistical significance in RANTES of preoperative serum and intraoperativeperitoneal fluid between the two groups (P>0.05). At 6 months after surgery, the serum RANTES level in thestudy group was lower than that in the control group [(29.0±9.1) vs (47.6±8.8) ng/L, P<0.05]. At 6 months
after surgery, the levels of CD3+, CD4+ and CD4+/CD8+ in the peripheral blood of the study group were higherthan those in the control group, however the level of CD8+ was lower than that in the control group withstatistical significance (all P<0.05). Conclusions ETCY combined with GES is more effective in treatmentof EMS comparing to ETCY alone, without more associated adverse reactions, and has advantages in downregulatingRANTES and improving cellular immune function. It is worthy to clinical application.
|
|
Received: 03 May 2019
Published: 23 April 2020
|
|
|
|
|
|
